The estimated Net Worth of & Jane Hoffman 2013 Descend... is at least 4.52 百万$ dollars as of 20 February 2014. Descend owns over 143,480 units of Onconova Therapeutics Inc stock worth over 4,518,275$ and over the last 11 years sold ONTX stock worth over 0$.
has made over 6 trades of the Onconova Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently bought 143,480 units of ONTX stock worth 1,215,276$ on 20 February 2014.
The largest trade 's ever made was buying 1,000,000 units of Onconova Therapeutics Inc stock on 30 July 2013 worth over 15,000,000$. On average, trades about 205,079 units every 34 days since 2013. As of 20 February 2014 still owns at least 4,518,275 units of Onconova Therapeutics Inc stock.
You can see the complete history of Descend stock trades at the bottom of the page.
's mailing address filed with the SEC is 712 FIFTH AVENUE, 36TH FLOOR, , NEW YORK, NY, 10019.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over 1,631,795$ worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth 51,994,589$ . The most active insiders traders include Capital, Llc Armistice Capi...、Capital Management, Llc 683、Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of 294,478$. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth 8,666$.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: